We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01240863
First Posted: November 15, 2010
Last Update Posted: June 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )
  Purpose
The primary objective of this study is to evaluate efficacy of hydrocodone extended-release (ER) tablets compared with placebo in alleviating moderate to severe pain in patients with osteoarthritis or low back pain as assessed by the weekly Average Pain Intensity (API) at week 12.

Condition Intervention Phase
Chronic Pain Drug: Hydrocodone ER Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

Resource links provided by NLM:


Further study details as provided by Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. ):

Primary Outcome Measures:
  • Change From Baseline to Week 12 in Weekly Average Pain Intensity (wAPI) [ Time Frame: Baseline (end of Open-Label Titration Period), Week 12 of Double-blind Treatment Period ]

    The primary efficacy variable was the change from baseline to week 12 in the wAPI. The API over the previous 24 hours, based on the 11-point Numerical Rating Scale (NRS 11), was collected daily by e-diary. The Week 12 wAPI scores from the previous 7 days were calculated for each study visit and averaged. The baseline wAPI score was calculated by averaging API scores from 3 to 12 days when the successful dose of hydrocodone extended release was confirmed at the end of the open label titration period, before patients were randomly assigned study drug. In the case of missing week-12 data due to early withdrawal from the study, or excessive rescue medication usage, the wAPI for week 12 was imputed.

    The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain on a Likert-type scale in which 0 is no pain and 10 is the worst pain imaginable. Negative change from baseline values indicate lessening in pain intensity.



Secondary Outcome Measures:
  • Percentage of Participants Withdrawn From the Study During the Double-Blind Treatment Period By Reason [ Time Frame: Day 1 to Week 12 of the double-blind treatment period ]
    Percentage of participants who withdrew from the study during the double-blind treatment period. Withdrawal is due to any cause, including lack of efficacy.

  • Kaplan-Meier Estimates for Time to Discontinuation From the Study [ Time Frame: Day 1 to Week 12 of the double-blind treatment period ]
    Kaplan-Meier estimates for time to discontinuation from the study (due to any cause) was calculated as the number of days since participants were randomly assigned to study drug treatment, ie, the difference between the date the participants withdrew and the date participants were randomly assigned to study drug treatment. The censoring flag was set to 0 if a participant was withdrawn from study drug treatment early and was set to 1 if the participant completed the 12 week treatment period. Censoring time was calculated as the difference of treatment completion date (ie, date of last study drug administration) and date participant was randomly assigned to study drug treatment.

  • Participants With a Weekly Average Pain Intensity (wAPI) Increase From Baseline Exceeding 33% [ Time Frame: Baseline (end of Open-Label Titration Period), Weeks 1, 2, 4, 8, and 12 of the Double-blind treatment period ]

    The API over the previous 24 hours, based on the 11-point Numerical Rating Scale (NRS 11), was collected daily by e-diary. The wAPI scores from the previous 7 days were calculated for each study visit and averaged. The baseline wAPI score was calculated by averaging API scores from 3 to 12 days when the successful dose of hydrocodone extended release was confirmed at the end of the open label titration period, before patients were randomly assigned study drug.

    The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain on a Likert-type scale in which 0 is no pain and 10 is the worst pain imaginable.


  • Participants With a Weekly Average Pain Intensity (wAPI) Increase From Baseline Exceeding 50% [ Time Frame: Baseline (end of Open-Label Titration Period), Weeks 1, 2, 4, 8, and 12 of the Double-blind treatment period ]

    The API over the previous 24 hours, based on the 11-point Numerical Rating Scale (NRS 11), was collected daily by e-diary. The wAPI scores from the previous 7 days were calculated for each study visit and averaged. The baseline wAPI score was calculated by averaging API scores from 3 to 12 days when the successful dose of hydrocodone extended release was confirmed at the end of the open label titration period, before patients were randomly assigned study drug.

    The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain on a Likert-type scale in which 0 is no pain and 10 is the worst pain imaginable.


  • Weekly Average Pain Intensity (wAPI) Scores During the Double-blind Treatment Period [ Time Frame: Baseline (end of Open-Label Titration Period), Weeks 1, 2, 4, 8, and 12 of the Double-blind treatment period ]

    The API over the previous 24 hours, based on the 11-point Numerical Rating Scale (NRS 11), was collected daily by e-diary. The wAPI scores from the previous 7 days were calculated for each study visit and averaged. The baseline wAPI score was calculated by averaging API scores from 3 to 12 days when the successful dose of hydrocodone extended release was confirmed at the end of the open label titration period, before patients were randomly assigned study drug.

    The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain on a Likert-type scale in which 0 is no pain and 10 is the worst pain imaginable.


  • Weekly Average Worst Pain Intensity (WPI) Scores During the Double-blind Treatment Period [ Time Frame: Baseline (end of Open-Label Titration Period), Weeks 1, 2, 4, 8, and 12 of the Double-blind treatment period ]

    The WPI was recorded by the patient in the e-diary daily throughout the study, based on the Numeric Rating Scale (NRS-11). Participants were asked to select the number that best described their WPI over the previous 24 hours. Values were averaged for each week.

    The Numeric Rating Scale (NRS-11) is an 11-point scale for patient self-reporting of pain on a Likert-type scale in which 0 is no pain and 10 is the worst pain imaginable.


  • Clinician Assessment of Patient Function (CAPF) at Week 4 [ Time Frame: Week 4 of the Double-blind Treatment Period ]

    Clinicians assessed participants across 5 dimensions:

    • Patients general activities
    • Patients walking ability
    • Patients ability to work/perform activities of daily living
    • Patients relationships with others
    • Patients enjoyment of life

    Assessments are rated on a 7-point scale, in which 1 is very much worsened and 7 is very much improved since the start of the study.


  • Clinician Assessment of Patient Function (CAPF) at Week 8 [ Time Frame: Week 8 of the Double-blind Treatment Period ]

    Clinicians assessed participants across 5 dimensions:

    • Patients general activities
    • Patients walking ability
    • Patients ability to work/perform activities of daily living
    • Patients relationships with others
    • Patients enjoyment of life

    Assessments are rated on a 7-point scale, in which 1 is very much worsened and 7 is very much improved since the start of the study.


  • Clinician Assessment of Patient Function (CAPF) at Week 12 [ Time Frame: Week 12 of the Double-blind Treatment Period ]

    Clinicians assessed participants across 5 dimensions:

    • Patients general activities
    • Patients walking ability
    • Patients ability to work/perform activities of daily living
    • Patients relationships with others
    • Patients enjoyment of life

    Assessments are rated on a 7-point scale, in which 1 is very much worsened and 7 is very much improved since the start of the study.


  • Clinician Assessment of Patient Function (CAPF) at Endpoint [ Time Frame: Endpoint of the Double-blind Treatment Period (up to week 12) ]

    Clinicians assessed participants across 5 dimensions:

    • Patients general activities
    • Patients walking ability
    • Patients ability to work/perform activities of daily living
    • Patients relationships with others
    • Patients enjoyment of life

    Assessments are rated on a 7-point scale, in which 1 is very much worsened and 7 is very much improved since the start of the study.

    Endpoint values are the last observed postbaseline data.


  • Patient Assessment of Function (PAF) at Week 4 [ Time Frame: Week 4 of the Double-blind Treatment Period ]

    The PAF is a self-administered questionnaire used to measure patients' assessment of their own ability to function in normal activities. Answers to the 7 questions were rated on a 7 point scale in which 1 was very much worsened and 7 were very much improved since the start of the study.

    The seven functional areas are:

    • ability to go to work
    • ability to perform at work (includes both work outside the home and housework)
    • ability to walk
    • ability to exercise
    • ability to participate in social events
    • ability to have sex
    • ability to enjoy life

  • Patient Assessment of Function (PAF) at Week 8 [ Time Frame: Week 8 of the Double-blind Treatment Period ]

    The PAF is a self-administered questionnaire used to measure patients' assessment of their own ability to function in normal activities. Answers to the 7 questions were rated on a 7 point scale in which 1 was very much worsened and 7 were very much improved since the start of the study.

    The seven functional areas are:

    • ability to go to work
    • ability to perform at work (includes both work outside the home and housework)
    • ability to walk
    • ability to exercise
    • ability to participate in social events
    • ability to have sex
    • ability to enjoy life

  • Patient Assessment of Function (PAF) at Week 12 [ Time Frame: Week 12 of the Double-blind Treatment Period ]

    The PAF is a self-administered questionnaire used to measure patients' assessment of their own ability to function in normal activities. Answers to the 7 questions were rated on a 7 point scale in which 1 was very much worsened and 7 were very much improved since the start of the study.

    The seven functional areas are:

    • ability to go to work
    • ability to perform at work (includes both work outside the home and housework)
    • ability to walk
    • ability to exercise
    • ability to participate in social events
    • ability to have sex
    • ability to enjoy life

  • Patient Assessment of Function (PAF) at Endpoint [ Time Frame: Endpoint of the Double-blind Treatment Period (up to week 12) ]

    The PAF is a self-administered questionnaire used to measure patients' assessment of their own ability to function in normal activities. Answers to the 7 questions were rated on a 7 point scale in which 1 was very much worsened and 7 were very much improved since the start of the study.

    The seven functional areas are:

    • ability to go to work
    • ability to perform at work (includes both work outside the home and housework)
    • ability to walk
    • ability to exercise
    • ability to participate in social events
    • ability to have sex
    • ability to enjoy life

    Endpoint values are the last observed postbaseline data.


  • Clinician Global Impression of Severity (CGI-S) of Illness Scores During the Double-blind Treatment Period [ Time Frame: Baseline (end of Open-Label Titration Period), Weeks 1, 2, 4, 8, and 12 of the Double-blind treatment period ]

    The CGI-S is a clinician-rated scale that assesses the severity of the patient's pain condition and response to the treatment. Severity of illness, as related to moderate to severe pain, consists of the following 7 categories:

    • 1 normal-shows no sign of illness,
    • 2 borderline ill,
    • 3 mildly (slightly) ill,
    • 4 moderately ill,
    • 5 markedly ill,
    • 6 severely ill, and
    • 7 among the most extremely ill (Guy 1976).

    The clinician assesses the severity of the patient's condition, based on the clinician's total clinical experience with patients with this condition, in response to treatment.

    Endpoint values are the last observed postbaseline data.


  • Short-Form Health Survey (SF-36) Physical and Mental Component Summary Scores at Baseline, Week 12 and Endpoint [ Time Frame: Baseline (end of Open-Label Titration Period), Week 12 and Endpoint (last visit up to week 12) of the Double-blind treatment period ]
    SF-36 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales. The PCS is represented by 4 subscales: physical function, role limitations due to physical problems, pain, and general health perception. The MCS is represented by 4 subscales: vitality, social function, role limitations due to emotional problems, and mental health. Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). PCS and MCS scores are constructed as a T-score with a mean of 50 and standard deviation of 10 and no minimum or maximum score; higher scores indicate better health status.

  • Brief Pain Inventory - Short Form (BPI-SF) Pain Interference Mean Score During the Double-Blind Treatment Period [ Time Frame: Baseline (end of Open-Label Titration Period), Weeks 1, 2, 4, 8, 12 and Endpoint (last visit up to week 12) of the Double-blind treatment period ]
    For pain interference, the BPI-SF used numerical scales to measure how much pain had interfered with 7 daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep in the past 24 hours. The scale used an 11 point Likert scale; range: 0 [does not interfere] to 10 [completely interferes]. BPI pain interference was typically scored as the mean of the 7 interference items. This mean could be used if at least 4 of 7 items had been completed on a given administration.

  • Participants With Adverse Events [ Time Frame: Day 1 up to Day 52 in Open-Label Titration; Day 1 up to Day 128 in Double-Blind Treatment period ]
    An adverse event (AE) was defined in the protocol as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

  • Participants With Potentially Clinically Significant Abnormal Vital Signs Values During the Double-Blind Treatment Period [ Time Frame: Day 1 up to Day 128 in Double-Blind Treatment period ]

    Data represents participants with potentially clinically significant (PCS) vital sign values.

    Significance criteria

    • Pulse - high: >=120 and increase of >= 15 beats/minute from baseline
    • Pulse - low: <=50 and decrease of >=15 beats/minute
    • Systolic blood pressure - high: >=180 and increase >=20 mmHg
    • Systolic blood pressure - low: <=90 and decrease >=20 mmHg
    • Diastolic blood pressure - high: >=105 and increase of >=15 mmHg
    • Diastolic blood pressure - low: <=50 and decrease of >=15 mmHg

  • Participants With Potentially Clinically Significant Abnormal Laboratory Values During the Double-Blind Treatment Period [ Time Frame: Day 1 up to Day 128 in Double-Blind Treatment period ]

    Data represents participants with potentially clinically significant abnormal serum chemistry, hematology and urinalysis values.

    Significance criteria:

    • Blood urea nitrogen: >=10.71 mmol/L
    • Uric acid: M>=625, F>=506 μmol/L
    • Hemoglobin: M<=115, F<=95 g/dL
    • Hematocrit: M<0.37, F<0.32 %
    • Urinalysis: blood (hemoglobin) and total protein: >=2 unit increase from baseline

  • Subjective Opiate Withdrawal Scales (SOWS) Scores During the Double-Blind Treatment Period [ Time Frame: Weeks 1, 2, 4, 8, 12 and Endpoint (last visit up to Week 12) of the Double-blind treatment period ]
    The results of the SOWS were collected in the e-diary daily during the first 4 weeks of the double blind treatment period and then during clinic visits at weeks 8 and 12 or early termination. The SOWS was a self administered questionnaire used to measure a participant's signs and symptoms of withdrawal from opiates. The scale contained 16 symptoms (eg, my nose is running; I feel restless), the participant rated the intensity on a scale of 0 (not at all) to 4 (extremely) for a total score of 0-64. The daily total score for the first 4 weeks was the largest score observed during the time period preceding that visit. For example, the week 1 score for each participant was the largest total score on any day between baseline and the night before the week 1 visit; the week 4 score for each participant was the largest score observed between the week 2 visit and the night before the week 4 visit.

  • Clinical Opiate Withdrawal Scales (COWS) Scores During the Double-Blind Treatment Period [ Time Frame: Baseline (end of Open-Label Titration Period), Weeks 1, 2, 4, 8, 12 and Endpoint (last visit up to Week 12) of the Double-blind treatment period ]

    The COWS was a clinician rated scale used to measure a participant's signs and symptoms of withdrawal from opiates, with ratings based only on apparent relationship to withdrawal. The COWS was performed at day 0 and weeks 1, 2, 4, 8, and 12 (double blind treatment period) or early termination. The scale contained 11 signs/symptoms whose intensity the clinician rated on a scale of 0 to 4 or 5.

    A total score was calculated as the sum of the responses to the 11 signs/symptoms for a total range of 0-48. Withdrawal severity was classified, based on the total score, as follows:

    • 0 to 4=normal
    • 5 to 12=mild
    • 13 to 24=moderate
    • 25 to 36=moderately severe
    • >36=severe

  • Addiction Behavior Checklist (ABC) Total Scores During Both the Open-Label Titration and Double-Blind Treatment Periods [ Time Frame: Baseline for Open-Label Titration period, Baseline for Double-Blind Treatment period (which is also the end of the Open-Label Titration period), Weeks 1, 4, 8, 12, and Endpoint (last visit up to Week 12) of the Double-blind Treatment period ]

    The ABC was a clinician rated scale that consisted of a brief (20 item) questionnaire designed to track behaviors characteristic of addiction related to prescription opioid medications in chronic pain populations. Items were focused on observable behaviors noted both during and between clinic visits. Each affirmative response was counted as one point, and points were added to calculate the total score, consequently resulting in scores ranging from 0 to 20 (0=no addiction-related behaviors seen and higher scores indicating an increasing number of addition-related behaviors seen).

    The ABC was to be performed at visits 2 and 7 (beginning and end of Open-label Titration period) and weeks 1, 4, 8, and 12 (Double-blind Treatment period) or early termination.


  • Current Opioid Misuse Measures (COMM) Total Scores During Both the Open-Label Titration and Double-Blind Treatment Periods [ Time Frame: Baseline for Open-Label Titration period, Baseline for Double-Blind Treatment period (which is also the end of the Open-Label Titration period), Weeks 1, 4, 8, 12, and Endpoint (last visit up to Week 12) of the Double-blind Treatment period ]

    The COMM was a clinician rated scale developed as a brief self report measure of current aberrant drug-related behavior for patients with chronic pain who were already on long term opioid therapy. A total score was calculated as the sum of the 17 questions. The total score ranged from 0 to 68. A score of 0 indicates no aberrant drug-related behaviors were seen. Patients with a total score of 9 or greater were classified as exhibiting aberrant drug-related behavior.

    The COMM was to be performed at visits 2 and 7 (beginning and end of Open-label Titration period) and weeks 1, 4, 8, and 12 (Double-blind Treatment period) or early termination.


  • Change From Baseline to Endpoint in the Double-Blind Treatment Phase in Electrocardiogram (ECG) Parameters [ Time Frame: Baseline (end of Open-Label Titration Period), Endpoint (last visit up to Week 12) of the Double-blind treatment period ]
    A 12-lead ECG was conducted at baseline and the last visit during the double-blind treatment period (week 12, or early termination).


Enrollment: 391
Study Start Date: November 2010
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the treatment period, participants were administered placebo tablets every 12 hours that matched the dosage deemed successful for managing their pain during the titration period. A step-wise, double-blind schedule to tamper off active drug was implemented during the first 2 weeks of the 12-week, double-blind, placebo-controlled treatment period to reduce the risk of withdrawal effects in participants randomly assigned to placebo.
Drug: Hydrocodone ER

During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.

Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.

Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.

Other Names:
  • CEP-33237
  • Hydrocodone bitartrate extended-release
Drug: Placebo

Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.

Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.

Experimental: Hydrocodone ER
Participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours at the dosage deemed successful for managing their pain during the titration period. During the 12-week, double-blind, placebo-controlled treatment period, participants randomly assigned to hydrocodone ER were administered tablets every 12 hours at the dosage deemed successful for managing their pain during the titration period.
Drug: Hydrocodone ER

During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.

Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.

Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.

Other Names:
  • CEP-33237
  • Hydrocodone bitartrate extended-release

Detailed Description:

The study consisted of a screening period of approximately 7 to 14 days, an open label titration period of up to 6 weeks, and a double blind treatment period of 12 weeks.

Participants entered the open label titration period and received hydrocodone ER tablets beginning with 15 mg every 12 hours for 3 to 7 days. The objective of the open label titration period was to find the successful dose of hydrocodone ER tablets that produced stable pain relief (defined as an Average Pain Intensity (API) score of 4 or less on the 11-point numerical rating scale for either 3 consecutive days or 3 out of 5 consecutive days while the patient was maintained on the same dose of study drug for up to 7 days). Patients returned to the study center prior to each dose adjustment.

Participants who met the criterion of a stabilized dose were randomly assigned into the 12 week, double blind, placebo controlled treatment period on the final day of the open label titration period (baseline visit). Patients began treatment with double blind study drug at the effective dose of hydrocodone ER tablets achieved during the titration period or matching placebo. Rescue medication was permitted in addition to the study drug during the double blind treatment period.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The patient is able to speak English and is willing to provide written informed consent, including a written opioid agreement, to participate in this study.
  • The patient must be willing and able to successfully self-administer the study drug, comply with study restrictions, complete the electronic diary, and return to the clinic for scheduled study visits as specified in this protocol.
  • Women of childbearing potential (not surgically sterile or 2 years postmenopausal), must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study, and have a negative pregnancy test at screening.
  • The patient has pain of at least 3 months' duration associated with osteoarthritis or low back pain.
  • The patient reports an average pain intensity score, over the prior 24 hours, of 5 or more on the 11-point numerical rating scale.
  • If the patient is receiving physical therapy, biofeedback therapy, acupuncture therapy, or herbal remedies, these therapies must remain unchanged during the study.
  • The patient must not participate in other study involving an investigational agent while enrolled into the present study.

Exclusion Criteria:

  • The patient has known or suspected hypersensitivities, allergies, or other contraindications to any ingredient in the study drug.
  • The patient has a recent history (within 5 years) or current evidence of alcohol or other substance abuse with the exception of nicotine or caffeine.
  • The patient has medical or psychiatric disease that, in the opinion of the investigator, would compromise collected data.
  • The patient is taking a total (ie, around-the-clock plus rescue medication) of more than 135 mg/day of oxycodone, or equivalent, during the 14 days prior to screening.
  • The patient has a history of suicidality.
  • The patient is expected to have surgery during the study.
  • The patient's primary painful condition under study is related to any source of chronic pain other than osteoarthritis or low back pain.
  • The patient is pregnant or lactating.
  • The patient has active malignancy.
  • The patient has human immunodeficiency virus (HIV).
  • In the judgment of the investigator, the patient has any clinically significant deviation from normal in the physical examination and/or clinical laboratory test values.
  • The patient has cardiopulmonary disease that would, in the opinion of the investigator, significantly increase the risk of treatment with opioids.
  • The patient has participated in a study involving an investigational drug in the previous 30 days.
  • The patient has received a monoamine oxidase inhibitor (MAOI) within 14 days before the first treatment with study drug.
  • The patient has any other medical condition or is receiving concomitant medication/therapy (e.g., regional nerve block) that would, in the opinion of the investigator, compromise the patient's safety or compliance with the study protocol, or compromise collected data.
  • The patient is involved in active litigation in regard to the pain currently being treated.
  • The patient has a positive urine drug screen (UDS) that is not medically explainable.
  • The investigator feels that the patient is not suitable for the study for any reason.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01240863


  Hide Study Locations
Locations
United States, Alabama
Horizon Research Group LLC
Mobile, Alabama, United States, 36608
United States, Arizona
Radiant Research, Inc.
Chandler, Arizona, United States, 85225
Radiant Research, Inc.
Scottsdale, Arizona, United States, 85251
Radiant Research Inc.
Tucson, Arizona, United States, 85710
United States, California
Physician Alliance Research Center
Anaheim, California, United States, 92804
Associated Pharmaceutical Research Center, Inc.
Buena Park, California, United States, 90620
Providence Clinical Research
Burbank, California, United States, 91505
Synergy Clinical Research
Escondido, California, United States, 92025
Research Center of Fresno, Inc.
Fresno, California, United States, 93726
Pacific Coast Pain Management Center
Laguna Hills, California, United States, 92637
South Orange County Surgical Medical Group
Laguna Hills, California, United States, 92653
Robert M. Karns, MD A Medical Corporation
Los Angeles, California, United States, 90036
Accelovance, Inc.
San Diego, California, United States, 92108
Radiant Research, Inc.
Santa Rosa, California, United States, 95405
Bayview Research Group, LLC
Valley Village, California, United States, 91607
United States, Colorado
Radiant Research, Inc
Denver, Colorado, United States, 80239
United States, Florida
Clinical Research of West Florida, Inc.
Clearwater, Florida, United States, 33765
Avail Clinical Research, LLC
DeLand, Florida, United States, 32720
International Research Associates, LLC
Miami, Florida, United States, 33183
Compass Research
Orlando, Florida, United States, 32806
Radiant Research, Inc.
Pinellas Park, Florida, United States, 33781
Gold Coast Research LLC
Plantation, Florida, United States, 33317
Sarasota Pain Medicine Research LLC
Sarasota, Florida, United States, 34238
Clinical Research of West Florida, Inc.
Tampa, Florida, United States, 33603
United States, Georgia
Drug Studies America
Marietta, Georgia, United States, 30060
Georgia Institute for Clinical Research, LLC
Marietta, Georgia, United States, 30060
Better Health Clinical Research, Inc.
Newnan, Georgia, United States, 30265
United States, Illinois
Millennium Pain Center
Bloomington, Illinois, United States, 61701
Medex Healthcare Research, Inc.
Chicago, Illinois, United States, 60603
United States, Indiana
Rehabilitation Associates of Indiana
Indianapolis, Indiana, United States, 46250
United States, Kansas
International Clinical Research, Inc.
Leawood, Kansas, United States, 66211
United States, Kentucky
Community Research
Crestview, Kentucky, United States, 41017
The Pain Treatment Center of the Bluegrass
Lexington, Kentucky, United States, 40503
United States, Louisiana
Horizon Research Group, LLC
Baton Rouge, Louisiana, United States, 70809
WK River Cities Clinical Research Center
Shreveport, Louisiana, United States, 71105
United States, Maryland
MidAtlantic Pain Medicine Center
Pikesville, Maryland, United States, 21208
United States, Massachusetts
Beacon Clinical Research, LLC
Brockton, Massachusetts, United States, 02301
United States, Missouri
HealthCare Research
Florissant, Missouri, United States, 63031
Medex Healthcare Research Inc.
Saint Louis, Missouri, United States, 63117
Sundance Clinical Research, LLC
Saint Louis, Missouri, United States, 63141
United States, Nebraska
Meridian Clinical Research
Omaha, Nebraska, United States, 68134
United States, Nevada
Clinical Research Center of Nevada
Las Vegas, Nevada, United States, 89104
United States, New Jersey
Advanced Pain Consultants
Voorhees, New Jersey, United States, 08043
United States, New York
Upstate Clinical Research Associates
Williamsville, New York, United States, 14221
United States, North Carolina
Wake Research Associates
Raleigh, North Carolina, United States, 27612
United States, Ohio
Radiant Research, Inc
Akron, Ohio, United States, 44311
Sterling Research Group, Ltd.
Cincinnati, Ohio, United States, 45219
Community Research, Inc
Cincinnati, Ohio, United States, 45227
Community Research, Inc
Cincinnati, Ohio, United States, 45245
Rapid Medical Research
Cleveland, Ohio, United States, 44122
Columbus Clinical Research
Columbus, Ohio, United States, 43213
United States, Oklahoma
SP Research
Oklahoma City, Oklahoma, United States, 73112
United States, Oregon
Pain Research of Oregon
Eugene, Oregon, United States, 97401
Summit Research Network Inc.
Portland, Oregon, United States, 97210
United States, Pennsylvania
Brandywine Clinical Research
Downingtown, Pennsylvania, United States, 19335
Tipton Medical and Diagnostic Center
Tipton, Pennsylvania, United States, 16684
AMH Feasterville Family Health Care Center
Trevose, Pennsylvania, United States, 19053
Clinical Research Center of Reading
Wyomissing, Pennsylvania, United States, 19610
United States, Rhode Island
Omega Medical Research
Warwick, Rhode Island, United States, 02886
United States, South Carolina
Radiant Research Inc.
Anderson, South Carolina, United States, 29621
Greenville Pharmaceutical Research
Greenville, South Carolina, United States, 29615
Radiant Research, Inc
Greer, South Carolina, United States, 29651
Trident Institute of Medical Research, LLC
North Charleston, South Carolina, United States, 29406
South Carolina Pharmaceutical Research
Spartanburg, South Carolina, United States, 29303
United States, Texas
KRK Medical Research
Dallas, Texas, United States, 75230
Radiant Research Dallas
Dallas, Texas, United States, 75231
Renaissance Clinical Research & Hypertension of Texas, PLLC
Dallas, Texas, United States, 75235
Medstar Clinical Research
Houston, Texas, United States, 77083
Benchmark Research
San Angelo, Texas, United States, 76904
DCT-Sugarland, LLC
Sugar Land, Texas, United States, 77478
Hillcrest Family Health Centers
Waco, Texas, United States, 76710
United States, Utah
Aspen Clinical Research, LLC
Orem, Utah, United States, 84058
Lifetree Clinical Research
Salt Lake City, Utah, United States, 84106
Sponsors and Collaborators
Teva Branded Pharmaceutical Products, R&D Inc.
Investigators
Study Director: Sponsor's Medical Expert, MD Cephalon
  More Information

Responsible Party: Teva Branded Pharmaceutical Products, R&D Inc.
ClinicalTrials.gov Identifier: NCT01240863     History of Changes
Other Study ID Numbers: C33237/3079
First Submitted: November 10, 2010
First Posted: November 15, 2010
Results First Submitted: February 19, 2017
Results First Posted: June 5, 2017
Last Update Posted: June 5, 2017
Last Verified: June 2017

Keywords provided by Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. ):
osteoarthritis
low back pain
Moderate to Severe Pain

Additional relevant MeSH terms:
Osteoarthritis
Back Pain
Low Back Pain
Chronic Pain
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Hydrocodone
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Antitussive Agents
Respiratory System Agents